BRAF and melanoma: Activating mutations in cytoplasmic serine/threonine kinase B-Raf (BRAF), belonging to the mitogen-activated protein kinase (MAPK) signaling pathway, are the most frequent genetic alterations present in approximately 50% of all melanoma cases [5].